SLC5A2 and heart failure: While there is strong and consistent evidence that SGLT2 inhibitors reduce heart failure hospitalization across both diabetic and non-diabetic patients with heart failure, GLP-1 receptor agonists did not show convincing benefits for heart failure patients.